CA-CEPTON-TECHNOLOGIES
9.9.2019 15:02:04 CEST | Business Wire | Press release
CNL Software, a world leader in Physical Security Information Management (PSIM) software, is pleased to announce a technology partnership with Cepton Technologies, a developer of industry-leading 3D sensing solutions, at the GSX in Chicago. The partnership will drive the automation of threat detection, tracking and escalation in real time using the latest PSIM, LiDAR and video assessment technologies.
Cepton Technologies’ Helius™ system is a smart lidar network utilizing edge computing to provide real-time detection, tracking and classification. It can seamlessly track an object from sensor to sensor, providing 3D data on location, dimensions, and velocity, while maintaining the same identification of the object.
By connecting multiple laser-powered sensors, it offers comprehensive coverage of a given area as well as high resolution imaging of objects. Sensors can be clustered as needed but act as one to maximize the simplicity of use and integration. With the in-built software in the hardware unit, Helius is browser-based and can launch on computers and mobile devices for instant monitoring and configuration, without installations of additional software. Furthermore, being edge-based, Helius processes data locally and outputs low-bandwidth data to the central server.
“CNL Software is committed to working with new and innovative technologies that will give our customers improved security and greater efficiency. Cepton’s lidar sensor technology brings the technological leaps that have taken place in autonomous vehicles to the security industry, especially in the government and critical infrastructure markets where we are experiencing growing demand for the integration of multiple different security system and sensor technologies,” comments Keith Bloodworth, CEO, CNL Software. “When integrated with IPSecurityCenterTM , Helius further enhances the industry’s most comprehensive PSIM system solution, providing users with access to more of the tools they need to quickly see, understand, assess and properly resolve perimeter security and surveillance incidents, consistently.”
Neil Huntingdon, Cepton’s VP of Business Development, added: “Our technology’s ability to detect and track events in traditionally difficult environments combined with IPSecurityCenter’s ability to correlate this data with data from other security systems and sensors and provide decision support is a powerful proposition. We’re really excited to be partnering with CNL Software to bring this game changing solution to the government, critical infrastructure, safe city and transportation markets, in particular. It will unlock that ‘missing layer’ by filling the medium-range sensor gap and improve it with the capability to classify objects as well as behaviors.”
For more information about CNL Software’s PSIM solution and deployments, please visit Booth #1713 at the GSX in Chicago on September 10– 12 2019. To book a demonstration, please email marketing@cnlsoftware.com
About Cepton Technologies, Inc.
Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.
Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.
Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines. For more information, visit: http://www.cepton.com/ .
Cepton will also have a separate booth at stand 1894, next to the bistro.
About CNL Software
More than a decade ago, we set out to create a PSIM platform to transform the way organizations manage their physical security. Today, IPSecurityCenter is trusted by the best-informed security operations in national security, critical infrastructure and large enterprises around the world. For more information, visit www.cnlsoftware.com .
Physical Security Information Management (PSIM) LinkedIn Group
The PSIM Group brings together users, integrators, consultants and manufacturers of Physical Security Information Management software to share ideas, thought leadership, tips, tricks, future developments and more! Please follow visit https://www.linkedin.com/groups/2162880
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
